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Abstract
Background: In Alzheimer’s disease, stroke and brain injuries, activated microglia can release proinflammatory
cytokines, such as interleukin (IL)-1β. These cytokines may change astrocyte and neurotrophin functions, which
influences neuronal survival and induces apoptosis. However, the interaction between neuroinflammation and
neurotrophin functions in different brain conditions is unknown. The present study hypothesized that acute and
subacute elevated IL-1β differentially modulates glial and neurotrophin functions, which are related to their role in
neuroprotection and neurodegeneration.
Method: Rats were i.c.v. injected with saline or IL-1β for 1 or 8 days and tested in a radial maze. mRNA and protein
expressions of glial cell markers, neurotrophins, neurotrophin receptors, β-amyloid precursor protein (APP) and the
concentrations of pro- and anti-inflammatory cytokines were measured in the hippocampus.
Results: When compared to controls, memory deficits were found 4 days after IL-1 administrations, however the
deficits were attenuated by IL-1 receptor antagonist (RA). Subacute IL-1 administrations increased expressions of
APP, microglial active marker CD11b, and p75 neurotrophin receptor, and the concentration of tumor necrosis
factor (TNF)-α and IL-1β, but decreased expressions of astrocyte active marker glial fibrillary acidic protein (GFAP),
brain-derived neurotrophic factor (BDNF) and TrK B. By contrast, up-regulations of NGF, BDNF and TrK B expressions
were found after acute IL-1 administration, which are associated with the increase in both glial marker expressions
and IL-10 concentrations. However, TrK A was down-regulated by acute and up-regulated by subacute IL-1
administrations. Subacute IL-1-induced changes in the glial activities, cytokine concentrations and expressions of
BDNF and p75 were reversed by IL-1RA treatment.
Conclusion: These results indicate that acute and subacute IL-1 administrations induce different changes toward
neuroprotection after acute IL-1 administrations but neurodegeneration after subacute ones.
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Background
In the last two decades, many studies have found that
neuroinflammation is causally related to the onset and
progress of several neurodegenerative disorders, including
Alzheimer’s disease (AD). Increased microglial activity and
pro-inflammatory cytokine releases may contribute to
neuronal dysfunction and death in neurodegenerative dis-
eases [1,2]. Among many inflammatory triggers and medi-
ators, both experimental and clinical data have suggested
IL-1β as the most potent pro-inflammatory cytokine in
neurodegeneration. First, a genetic study has shown that
the inheritance of a specific IL-1 gene polymorphism is as-
sociated with an earlier age of AD onset and increases the
risk for AD development by as much as six-fold [3]. Sec-
ond, IL-1β cultured with cortical neurons has been found
to increase mRNA expressions and the concentration of
amyloid precursor proteins (APP), neuropathological
markers of AD [3,4]. Third, our team has previously
reported that subacute administration of IL-1β to rats can
reduce acetylcholine (ACh) release and impair memory
[5]. Therefore, IL-1 administration to rodents has been
popularly used as a model for studying the interaction be-
tween inflammation, brain functions, and memory deficits
in neurodegenerative and psychiatric diseases [6,7].
However, neuroinflammation has two sides; it may be
beneficial in promoting homeostasis and neuron survival,
but can also result in tissue injury through the over-action
of inflammatory mediators. Even though many studies
have reported that increased IL-1 release contributes
to neurodegeneration in both acute and chronic brain
conditions, findings from acute ischemia, stroke and brain
injuries show that the release of IL-1 and other pro-
inflammatory cytokines, such as TNF-α, may protect
neurons [8-12]. However, many studies have demonstrated
that blocking IL-1 or reducing inflammation could reduce
neuron death and symptoms of disability as well as save
patients’ lives [13]. This conflict raises important ques-
tions: whether and how acute and subacute or chronic IL-
1 releases differentially modulate central nervous system
(CNS) functions, which may result in opposite effects dur-
ing different brain conditions. To answer this question,
the pro- and anti-inflammatory mechanisms and the
neuroprotective system in the brain should be compared
in acute and 8-day repeated IL-1-induced models.
It is well known that in different brain diseases, both
activated microglia and astrocytes can produce pro-
inflammatory, anti-inflammatory and neurotrophic fac-
tors. However, microglia may be more involved in the
inflammatory response in neuropathological conditions,
while astrocytes may have more supporting and main-
taining functions, including releasing neurotrophins and
anti-inflammatory cytokines. Neurotrophins and their
receptors compose a major neuroprotective system in the
brain because they stabilize and maintain homeostasis
(protection and repair), clean up neurotoxins, regulate
neurotransmission and modulate neuronal regenesis and
degenesis [14-17]. The most often studied neurotrophins
related to neurodegeneration are nerve growth factor
(NGF) and brain-derived neurotrophic factor (BDNF).
The highest mRNA levels of these neurotrophins have
been found in the hippocampus, which indicates their
important roles in neuroendocrine and cognitive behavior
[18]. Indeed, our research group previously reported
that the down-regulation of NGF mRNA expression
is correlated with the reduction of ACh release after IL-
administration for 8 days [5].
BDNF also plays a crucial role in cognition, learning,
and memory formation by modulating synaptic plasticity
and is, therefore, a critical molecule in dementia and
neurodegenerative diseases. Two types of neurotrophin
receptors have already been found: tyrosine kinases (TrK
A, B, C) and low-affinity NGF (p75) receptor [18]. The
receptor for NGF is TrK A and the receptor for BNDF is
TrK B, while both neurotrophins also combine with p75
receptors. The binding of neurotrophins to their TrK re-
ceptors causes signaling events, which promote neuron sur-
vival, whereas the activation of the p75 pathway may
trigger apoptosis or enhance the selectivity of neurotrophin
binding for specific TrKs [19,20]. Hence, neurotrophins
may activate different cellular mechanisms depending on
which type of receptors they interact with.
Recently, increasing evidence has suggested that
neuroinflammation may trigger neuroprotection or
neurodegeneration through the neurotrophic system
[21]. Increased and decreased expressions or concentra-
tions of neurotrophins have been reported in acute and
chronic neurodegenerative diseases. For example, both
IL-1 and NGF concentrations were markedly increased
in the frontal cortex within 24 hours of traumatic brain
injuries [22], and BDNF was found to be increased in
acute spinal cord injury [23-25]. In the brain of AD pa-
tients, increased or decreased NGF and BNDF mRNA or
protein expressions have been reported [18,26,27]. Fur-
thermore, TrK A and TrK B receptors have been shown
to be down-regulated in AD brains [18]. However, it is
unclear whether and how acute and subacute glial acti-
vation and IL-1 released in response to these different
conditions are related to changes in neurotrophin sys-
tems. The present study hypothesized that acute and
8-day repeated IL-1 administrations differentially modu-
late the activity of microglia and astrocytes, which may
change the inflammatory and neurotrophin systems,
thereby providing protective or degenerative effects on
brain functions such as memory and Aβ deposition. To
demonstrate this hypothesis, the present study evaluated 1)
the effects of 1-day (acute) and 8-day (subacute) IL-1
administrations on hippocampus-dependent working
memory in rats, and 2) the gene and protein expressions
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of the microglial active marker CD11b and astrocyte
marker glial fibrillary acidic protein (GFAP), APP,
neurotrophins and receptors, and their relationship with
pro- and anti-inflammatory cytokines in the hippocampus.
Materials and methods
Animals
Male Long-Evans rats (250 to 280 g, Charles River,
Quebec, Canada) were housed in pairs and maintained
under a 12-h light, 12-h dark cycle, room temperature at
21 ± 1°C, with food and water available ad libitum.
There were two independent experiments (EXP1 and
EXP2). In EXP1, rats were divided into four groups
of 10 as: 1) acute saline treatment (1 day); 2) acute IL-1
(1 day); 3) subacute saline (8 days) and 4) subacute IL-1
(8 days). In EXP2, rats were divided into two groups of
10 as: 1) subacute IL-1 (8 days) + saline, and 2) subacute
IL-1 (8 days) + IL-1 receptor antagonist (RA). Since we
previously showed that IL-1RA alone did not affect rat
memory and NGF expression [5], we did not study the
effects of IL-1RA in the control group. All procedures
were reviewed and approved by the Institutional Animal
Care and Use Committee in the University of Prince
Edward Island, in accordance with the guidelines of the
Canadian Council on Animal Care (06–004, 1001966).
The experimental design for EXP1 is presented in Dia-
gram 1. The experimental procedure for EXP2 was the
same as the EXP1.
Surgery
Following habituation for 1 week, animals were anesthe-
tized with ketamine (100 mg/kg) and xylazine (20 mg/kg)
and placed in stereotaxic apparatus. For intracerebroven-
tricular (i.c.v.) injections, guide cannulae (24-gauge) were
located stereotaxically over the right lateral ventricles (an-
terior/posterior=1 mm; medial/lateral=1.6 mm; 1 mm
depth) as described in detail elsewhere [28]. A dummy
cannula was screwed into the guide cannula to maintain
patency. The guide cannula protruding from a concentric
custom-made Derelin pedestal was secured to the skull
with three screws and dental cement. Tetracycline powder
was used to treat the wound. Animals were allowed to re-
cover for 10 days.
Behavioral training and testing
Foraging tests were conducted on an eight-arm radial
maze, consisting of an octagonal center platform (51 cm
in diameter, arm-to-arm) connected to eight equally
spaced arms (40 × 13 cm). Ten days after the surgery,
rats were food deprived to 90% of their free-feeding
weight and the delayed spatial win-shift version of the
radial maze task was adapted from Song et al. [28]. Each
trial consisted of a training phase and a memory test
phase, separated by a delay (from 5 minutes to 50
minutes). Before the training phase, four arms were ran-
domly baited with food pellets (Bioserv, French, NJ,
USA). The other arms were blocked. In the training
phase, each rat was allowed 5 minutes to retrieve the
food from the four open arms. During the memory test
phase, all arms were opened and rats were allowed to
explore the maze until they had retrieved food located in
the four arms that were blocked during training, or until
5 minutes had elapsed. An arm entry was defined as
movement along the arm to the food cup. Errors were
recorded as rat entries into unbaited arms. Criterion per-
formance during the memory tests was defined as five or
fewer arm entries to locate four food pellets. When cri-
terion performance at a 50-minute delay was maintained
for two consecutive days, saline or IL-1 was i.c.v.-
injected immediately after the training phase. Since our
previous two studies demonstrated that saline or IL-1
administration before the training phase did not signifi-
cantly impair animal learning [5,28], in the present study
injections were only carried out after the training phase
for comparing acute and subacute effects. At 45 minutes
after the injection, animal error entries were scored at
memory test phases. For the acute injection groups, ani-
mal behavior was tested only once after saline or IL-1
administration and animals were decapitated on day 2.
Controls that received saline injection for 2 days were
compared to the group treated with IL-1 for 2 days; the
controls that received saline injection for 3 days were
compared to the group treated with IL-1 for 3 days, and
so on for 8 days.
I.c.v. injections of IL-1β and IL-1RA
Rat recombinant IL-1 and IL-1RA were obtained from
R&D system Inc (Minneapolis, USA) and dissolved in
sterile, pyrogen-free saline at doses of 15 ng/10 μL/rat
for IL-1 and 100 ng/5 μL/rat for IL-1RA [5]. The dose
for IL-1β was based on those used in our previous study
(5, 10, and 50 ng) and on other studies (10 to 20 ng)
[29,30]. The method for IL-1 and IL-1RA injection was
the same as previously described [28]. In brief, rats were
gently handled for 2 weeks before the first injection. On
the injection day, 10 μL IL-1, IL-1+IL-1RA or saline was
drawn into an internal needle that was connected to a
micro-injector through a PE 50 polyethylene tube. IL-1,
IL-1RA or saline was slowly infused into the brain over
a period of 60 s. The injection needle was allowed to re-
main inside the guide cannula for 1 minute. Rats were
returned to their home cages for a 45-minute period be-
fore behavioral tests [28].
Determination of cannula locations
After decapitation, brains were rapidly removed and
placed on an ice block. The location of the cannula and
the injection site was confirmed in the coronal section
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of the brain under a microscope. The hippocampuses
were dissected quickly on ice and then frozen in N2. An-
imals with injection sites and probes outside of the lat-
eral ventricular were excluded from the data.
Quantitative PCR
In EXP1, mRNA expressions of CD11b, GFAP, NGF,
BDNF, TrK A, TrK B, p75 and APP were measured by
quantitative PCR in the hippocampus. The primer se-
quences for these genes and the internal control, β-actin
(Sigma, Canada), are listed in Table 1. The total RNA
was purified from brain tissues using RNeasy Mini Kit
(Qiagen). cDNA was synthesized from 2 μg total RNA
using the Ominiscript RT kit (Qiagen). Primer sequences
were purchased from Invitrogen (Carlsbad, CA, USA).
The real-time PCR reaction solution contained a final
volume of 15 μl QuantiTect SYBR Green PCR Mixture
providing a 2.5 mM MgCl2, 1pM each of the primers
and 0.5 μl cDNA templates. The real-time PCR was
optimized to run with conditions of the initial activation
at 95°C for 15 minutes, denaturation at 94°C for 15 s,
annealing at 55°C for 20 s, and extension at 72°C for
15 s with a single fluorescence measurement and up to
40 cycles. The specificity of the primers was validated
by agarose gel electrophoresis and real-time PCR to
ascertain that no non-specific products formed prior
to the sample analysis. The values were normalized
against the internal control, β-actin, since we previously
tried GAPDH to compare β-actin expressions in the
hippocampus, and did not find a significant difference
between these two house-keeping (HK) genes in the IL-
1-induced model.
Western blot
The rabbit origin antibodies for CD11 (160 KDa), GFAP
(50 KDa), BDNF (14 KDa), TrK A (140 KDa), TrK B
(95–145 KDa) and p75 (75 KDa) were purchased from
Santa Cruz Biotechnology, USA. The samples were spun
down at 5,000 rpm for 5 minutes following hippocampus
removal and homogenizing in the Teen buffer. The pel-
lets were lysed in the lysis buffer, and then spun down at
13,000 rpm for 10 minutes. After adding sample buffer
and boiling, the supernatant was collected and loaded to
SDS PAGE gels. After running the gels, the proteins
were transferred to nitrocellulose membranes. The pro-
teins were then blotted with specific primary and sec-
ondary antibodies. Proteins on the membranes were
detected by enhanced chemiluminescence (ECL) and
then developed with image film. The bands were
scanned and densitometrically analyzed using an auto-
matic image analysis system (NIH Image 1.61 software).
All target proteins were quantified by normalizing them
to β-actin re-probed on the same membrane and then
calculated as a percentage of the control group.
Measurement of NGF concentration by ELISA kit
β-NGF concentrations were measured in the hippocampus
by the ELISA kit, NGF Emaxtm ImmunoAssay System
number G7631 (R&D System, Promega, USA) following
the instructions provided by the manufacturer. The brain
tissues were homogenized with ultrasonication in an
extraction buffer (Tris-acetate 20 mM, pH 7.5, NaCl
150 mM, ethylenediamine-tetraacetic acid (EDTA) 1
mM, EGTA 1 mM, sodium-pyrophosphate 2.5 mM,
ortovanadate 1 mM, β-glycerolphosphate 1 mM, NaF
100 mM, phenylmethylsulfonyl fluoride (PMSF) 1 mM,
leupeptin 1 μg/mL) and centrifuged at 4°C for 20 minutes,
10,000 g, and supernatants were recovered with the solu-
tion (EDTA, PMSF). Briefly, 96-well immunoplates were
coated with 100 μL per well of polyclonal anti-NGF anti-
body. After an overnight incubation at 4°C, the plates were
washed once with wash buffer (Tris–HCl 20 mM, pH 7.6,
NaCl 150 mM, 0.05% Tween® 20) and then blocked for 1
h with the block & sample 1x buffer provided by the
manufacturer (200 μL/well). After washing, the samples
were incubated in the coated wells (100 μL each) for 6 h
at room temperature with shaking. After an additional five
washes the immobilized antigen was incubated with an
anti-NGF monoclonal antibody overnight at 4°C. The
plates were washed again with wash buffer, and then incu-
bated with an anti-rat IgG horseradish peroxidase (HRP)
conjugate (100 μL/well) for 2.5 h at room temperature.
Table 1 Primer sequences of quantitative PCR
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After another washing, the plates were incubated with a
tetramethyl benzidine (TMB)/peroxidase substrate solu-
tion for 15 minutes (100 μL/well), provided by the manu-
facturer). Reactions were then stopped with 100 μL/well 1
N HCl. The colorimetric reaction product was mea-
sured at 450 nm using a microplate reader (Dynatech
MR 5000, PBI International, USA). NGF concentrations
were determined from the regression line for the NGF
standard (ranging from 7.8 to 500 pg/mL purified NGF)
incubated under similar conditions in each assay. Under
these conditions the recovery of NGF in our assay
was >90%. The NGF sensitivity of the assay was about
3 pg/g of wet tissue, and cross-reactivity with other
related neurotrophic factors (BDNF, neurotrophin-3
and neurotrophin-4) was less than 3%. Data are represented
as ng/mL supernatant and all assays were performed
in duplicate.
Measurement of cytokine concentrations by Bio-Plex
protein array system
TNF-α, IL-1β and IL-10 were measured in the hippo-
campus as previously described [31]. In brief, a custom-
ized 3-plex rat cytokine panel consisting of fluorescent
beads for IL-1β, TNF-α and IL-10 (BioRad, CA, USA)
was analyzed with a Luminex protein suspension array
system (Bioplex 200, Biorad, CA, USA) according to
manufacturer’s instructions. Due to the large binding
surface of the beads, this assay is highly sensitive and
has been proven before to work well for detecting cyto-
kines from brain tissues [32]. The results were expressed
as pg/mL of brain supernatant.
Data analysis
The behavioral results were analyzed by two-way analysis
of variance (ANOVA); duration (acute or subacute) ×
treatment (saline or IL-1), with repeated measurement for
EXP1 and one-way ANOVA for EXP2. Results for mRNA
and protein expressions of glial markers, neurotrophins
and their receptors and cytokine concentrations were ana-
lyzed by two-way (duration × treatment) ANOVA for
EXP1 and one-way ANOVA for EXP2. The statistics were
expressed by F (=variance of the group means / mean of
the within group variances) with the degree freedom.
When P was <0.05 on ANOVA, the difference between
groups was assessed by Newman-Keuls post hoc test (GB-
STAT, Dynamic Microsystems, Inc., USA). Significance
was set at P <0.05. Results are expressed as mean ± stand-
ard error of the mean (SEM).
Results
Differential effects of acute and subacute IL-1 B
administration on working memory
Rats that received saline i.c.v. administration prior to
either the memory training or the testing phase of the
delayed working memory task were able to find the loca-
tion of food pellets in specific arms on the maze. These
rats were also able to utilize this information after a 50-
minute delay to select and enter a subset of four arms
that contained food (Figure 1, training A). The i.c.v. ad-
ministration of IL-1β prior to training had no effect on
the time taken or the number of arm choices to find
food rewards during the training period. However, two-
way ANOVA confirmed that the treatment factor signifi-
cantly affected the number of error entries during the
memory testing from day 5 to day 8 (day 5, F3,26 =
23.96, P <0.001; day 6, F3,26 =14.16, P <0.001; day 7,
F3,26 = 21.34, P <0.001; day 8, F3,26 = 22.19, P <0.001).
The post hoc test confirmed that IL-1 administrations
significantly increased the number of error entries dur-
ing testing phases on days 5, 6, 7 and 8 when compared
to the control group (P <0.01) (Figure 1A). 8 days re-
peated IL-1-induced memory impairment was reversed
by IL-1RA treatment (day 5, F1,18 = 7.53, P <0.05; day
6, F1,18 = 8.61, P <0.01; day 7, F1,18 = 10.32, P <0.01;
day 8, F1,18 = 8.74, P <0.01) (Figure 1B).
IL-1β administration-induced changes in CD11b and GFAP
expressions
Two-way ANOVA showed that both treatment and dur-
ation factors significantly changed gene expressions of
the microglial marker CD 11b (treatment: F1,27 = 13.07,
P <0.001; duration F1,27 = 7.48, P <0.05). The post hoc
revealed that significant up-regulation of CD11b mRNA
expression occurred in the group receiving 8 days of re-
peated IL-1 administration (P <0.01) (Figure 2A). At the
protein level, the ANOVA also indicated that the treat-
ment and duration factors had significant effects on
CD11b expressions (treatment: F1,27 = 41.5, P <0.0001;
duration F1,27 = 5.1, P <0.05) and that the interaction
between these two factors was also significant (F1, 27 =
4.95, P <0.05). The post hoc test revealed that IL-1 sig-
nificantly increased CD11b expression after both acute
(P <0.05) and subacute (P <0.0001) administrations,
whereas the increase was much greater in the group that
received subacute IL-1 injections (P <0.01) (Figure 2B).
With regards to astrocyte activation, two-way ANOVA
showed that the treatment factor significantly affected
GFAP protein but not mRNA expressions (treatment:
F1,27 = 23.46, P <0.001) (Figure 2C). The post hoc test
demonstrated that acute IL-1 significantly increased,
while 8 days repeated IL-1 decreased GFAP protein ex-
pressions (P <0.01) (Figure 2D).
Results from EXP2 demonstrated that IL-1RA treatment
for 8 days significantly attenuated subacute IL-1-induced
increase in CD11b and decreased GFAP expressions
at the protein level (mRNA expressions were not mea-
sured); CD11b: F1,18 = 9.91, P <0.01; GFAP: F1,18 = 7.72,
P <0.01) (Figure 2E and F).
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IL-1β administration-induced changes in the NGF and TrK
A system
Two-way ANOVA demonstrated that the factor of treat-
ment significantly changed NGF mRNA expressions and
concentrations in the hippocampus (mRNA: F1,38 = 7.2,
P <0.01; concentration: F1,27 = 6.57, p<0.05). The post hoc
test showed that acute IL-1 administration significantly
up-regulated NGF mRNA expressions and increased NGF
concentrations (P <0.05) (Figure 3A and B). However,
8 days repeated IL-1β administration did not significantly
change NGF mRNA expressions and concentrations
(Figure 3B).
With regards to the mRNA expressions of NGF recep-
tor TrK A, the ANOVA indicated that neither of two
factors had any significant effect on TrK A gene expres-
sions (Figure 3C). However, at the protein level, the
treatment factor significantly changed protein expres-
sions (F1,38 = 24.08, P <0.0001), and the interaction be-
tween the treatment and duration was also significant
(mRNA F1,33 = 10.34, P <0.01; protein: F1,27 = 9.59,
P <0.001). The post hoc test revealed that acute IL-1 ad-
ministrations markedly down-regulated TrK A protein
expressions (P <0.01) (Figure 3D). By contrast, 8 days re-
peated IL-1 administrations up-regulated this receptor
expression (P <0.01) (Figure 3D).
IL-1β administration-induced changes in the BDNF and
TrK B system
Two-way ANOVA indicated that the treatment factor
significantly changed BDNF gene and protein expres-
sions (mRNA: F1,38 = 8.71, P <0.001; protein: F1,27 =
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Figure 1 IL-1-induced changes in the number of entry error in 8-arm radial maze during testing phase. Before the training, 8 arms were
baited with a single 45-mg food pellet at the cup in the end of each arm. In the training phase, four arms chosen randomly were opened, and
the remaining arms were blocked. Each rat was allowed 5 minutes to retrieve the food from the four open arms. During the memory test phase,
all arms were opened and rats were allowed to explore the maze until they had retrieved food located in the four arms that were blocked
during training, or until 5 minutes had elapsed. Errors were recorded as entries into unbaited arms. (A) On day 5, subacute IL-1 significantly
increased the error number, **P <0.01 versus saline-treated group (n = 7). (B) IL-1 receptor antagonist (IL-1RA) reversed subacute IL-1-induced
changes in memory retrieval, *P <0.01 versus saline group (n = 8), # P <0.01 versus IL-1 group (n = 8).
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between these two factors (mRNA: F1,38 = 13.62, P <0.01;
protein: F1,27 = 17.97, P <0.001). The post hoc test indi-
cated that acute IL-1β administration significantly in-
creased BDNF mRNA expressions (P <0.05), while 8
days repeated IL-1 reduced BDNF expressions (P <0.05)
(Figure 4A). Protein expressions of BDNF were not signifi-
cantly changed by acute IL-1 administration, whereas,
consistent with the gene results, a significant reduction in
BDNF protein levels was found in the group with subacute
IL-1 administrations (P <0.05) (Figure 4B). This BDNF re-
duction induced by 8 days repeated IL-1RA treatment sig-
nificantly attenuated IL-1-induced decrease in BDNF
protein expressions (F1,18 = 13.62, P <0.01) (Figure 4E).
The IL-1 factor also affected TrK B expressions signifi-
cantly at both mRNA and protein levels (mRNA: F1,38 =
8.14, P <0.01; protein: F1,27 = 15.97, P <0.0001) as re-
vealed by two-way ANOVA. The post hoc test revealed a
similar pattern of changes in mRNA and protein expres-
sions of BDNF between groups. Thus, gene expressions of
TrK B were up-regulated after acute IL-1 administration
(P <0.05) (Figure 4C), but markedly down-regulated by 8
days repeated IL-1 administration (P <0.05) (Figure 4C).
At the protein level, the increase in TrK B did not reach
significance after acute IL-1 treatment, but a significant
CD11b protein
D
   GFAP protein





































































































































































Figure 2 Effects of acute and subacute IL-1β administrations on mRNA and protein expressions of microglial marker CD 11b and
astrocyte marker glial fibrillary acidic protein (GFAP), and the effect of IL-1RA treatment on subacute IL-1-induced changes in the rat
hippocampus. (A) CD 11b mRNA expressions; (B and E) CD 11b protein expressions; (C) GFAP mRNA expressions; (D and F) GFAP protein
expressions; *P <0.05; **P <0.01 versus the matched control group, #P <0.05 versus acute IL-1 group; ##P <0.01 versus the subacute IL-1 group
(mRNA n = 9 to 10; protein n = 7 to 8).
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reduction of TrK B protein level was found after 8 days re-
peated IL-1 administration (P <0.01) (Figure 4D). One way
ANOVA demonstrated that IL-1RA treatment signifi-
cantly reversed the TrK B expressions at the protein level
(F1,18 = 13.75, P <0.01) (Figure 4f).
IL-1β administrations-induced changes in the expressions
of p75 receptor and APP
As shown by Figure 4, the gene and protein expressions
of p75 receptor were changed significantly by the treat-
ment (mRNA: F1,38 = 25.34, P <0.0001; protein: F1,27 =
20.07, P <0.001), as indicated by two-way ANOVA. The
interaction between IL-1/saline treatment and duration
was also significant (mRNA: F1,38 = 23.54, P <0.0001; pro-
tein: F1,27 = 21.93, P <0.0001). The post hoc test demon-
strated that acute and subacute administration of IL-1β
exerted opposite effects on p75 receptors at gene and pro-
tein levels; acute IL-1 down-regulated mRNA and protein
expressions of p75 receptors (P <0.01), while 8 days
repeated IL-1 significantly increased both expressions
(P <0.01 and 0.05, respectively) (Figure 5A and B). In the
IL-1RA treated group, the increased in p75 protein ex-
pression was significantly lower when compared to sub-
acute IL-1 group (F1,18 = 7.92, P <0.01) (Figure 5C).
APP gene expressions were shown to be markedly af-
fected by both treatment and duration factors (treatment:
F1,38 = 13.02, P <0.01; duration: F1,38 = 10.98, P <0.01).
The interaction between these two factors was also signifi-
cant (F1,38 = 13.13, P <0.001). The post hoc test revealed
that there was no significant change in APP mRNA ex-
pressions in the group with acute IL-1 administration.
When compared to the group repeatedly treated with
saline for 8 days, a significantly up-regulation of APP
mRNA expressions was found in the hippocampal tis-
sues in the animals with 8 days repeated IL-1 adminis-
tration (P <0.01) (Figure 6A). On the other hand, the
effect of IL-1 on APP protein expressions only
approached significance (F1,27 = 4.33, P = 0.051), and
the interaction between IL-1 and treatment duration is
also only close to significant (F1,27 = 4.23, P = 0.054).
However, the post hoc test did not show any significant
changes between groups (Figure 6B).
IL-1 administration-induced changes in hippocampal IL-
1β, TNF-α and IL-10 concentrations
The effects of the treatment factor on hippocampal IL-
1β, TNF-α and IL-10 concentrations were significant
(IL-1: F1,31 = 7.28, P <0.01; TNF: F1,31 = 8.64, P <0.01;
IL-10: F1,31 = 7.14, P <0.01). The effects of treatment
duration on these three cytokines were also significant
(IL-1: F1,31 = 6.37, P <0.05; TNF: F1,31 = 9.72, P <0.01;




































































































Figure 3 Effects of acute and subacute IL-1β administrations on mRNA and protein expressions of neurotrophin nerve growth factor
and its receptor tyrosine kinase A in the rat hippocampus. (A) Nerve growth factor (NGF) mRNA expressions; B, NGF concentrations;
(C) tyrosine kinase (TrK)A mRNA expressions and (D) TrK A protein expressions. *P <0.05; **P <0.01 versus the matched control group (mRNA n = 9
to 10; protein n = 7).
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IL-1 administration did not change IL-1β concentrations
but significantly increased TNF-α and IL-10 concentra-
tions (P <0.01), while 8 days repeated IL-1 injection sig-
nificantly increased both IL-1β and TNF-α but reduced
IL-10 levels (P <0.05) when compared to the matched
saline treatment group (Table 2). IL-1RA treatment sig-
nificantly reduced IL-1 (F1,18 = 9.36, P <0.01) and TNF-
α (F1,18 = 7.81, P <0.01) concentrations; IL-1 (IL-1
group: 4,125.79 ± 513.36, IL-1 + IL-1RA group: 2,082.53
± 410.21) and TNF-α (IL-1 group: 1376.72 ± 226.81, IL-
1 + IL-1RA group: 395.421 ± 52.39).
Discussion
A summary and comparison of the results are presented
in Table 3. According to these results the following sev-
eral aspects are discussed.
Acute and subacute IL-1 administration differently
change glial activities, which may be related to
inflammation in the brain
Acute and higher dose (100 ng/rat) i.c.v. administration
of IL-1β has been found to activate microglia and astro-
cytes [33], which is similar to our findings in the present

















































































































































































Figure 4 Effects of acute and subacute IL-1β administrations on mRNA and protein expressions of brain-derived neurotrophic factor
and its receptor tyrosine kinase in the rat hippocampus. (A) Brain-derived neurotrophic factor (BDNF) mRNA expressions; (B and E) BDNF
protein expressions; (C) Tyrosine kinase (TrK) B mRNA expressions and (D and F) TrK B protein expressions. *P <0.05 versus acute control group;
#P <0.05, ##P <0.01 versus subacute control group and acute IL-1 group (A-D); #P <0.05 versus subacute IL-1 group (E,F) (mRNA n = 9 to 10;
protein n = 7 to 8).
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study. However, effects of chronic or subacute and low
dose of IL-1 administrations on glial activities, which
more accurately mirror the processes in neurodegenera-
tive diseases, were not reported. Interestingly, the
present study found that the increase in the protein ex-
pression of microglia marker CD11b was significantly
greater after 8 days repeated IL-1 injections than after
acute injections. Meanwhile, a more pronounced in-
crease in the concentrations of pro-inflammatory cyto-
kines was observed in the 8-day repeated IL-1 group
than in the acute IL-1 group. Results from a mouse
model of inducible sustained IL-1β overexpression bred
with a triple transgenic mouse model of AD support our
finding. In this model, greater microglial activation was

























































































Figure 5 Effects of acute and subacute IL-1β administrations on
mRNA and protein expressions of p75 receptor in the rat
hippocampus. (A) p75 mRNA expressions; (B and C) p75 protein
expressions. *P <0.05, **P <0.01 versus acute control group; #P <0.05,
##P < 0.01 versus control group and acute IL-1 group (A,B);
##P < 0.01 versus subacute IL-1 group (C) (mRNA n = 9 to 10;































































Figure 6 Effects of acute and subacute IL-1β administrations on
mRNA and protein expressions of amyloid precursor protein in
the rat hippocampus. (A) Amyloid precursor protein (APP) mRNA
expressions; (B) APP protein expressions; ##P <0.01 versus subacute
control group and acute IL-1 group (mRNA n = 9 to 10; protein
n = 7).
Song et al. Journal of Neuroinflammation 2013, 10:59 Page 10 of 15
http://www.jneuroinflammation.com/content/10/1/59
[34]. On the other hand, changes in anti-inflammatory
cytokine IL-10 and neurotrophins induced by acute and
8 days repeated IL-1 administration presented opposite
effects. It is known that microglial, endothelial cells and
astrocytes can produce anti-inflammatory cytokines, such
as IL-10, while astrocytes can also produce neurotrophins
[35,36]. In the present study, the up-regulation of GFAP
expression and moderately increased CD11b expression
were associated with increased IL-10 concentrations after
acute IL-1 administration. However, a decrease in mRNA
expressions of GFAP and a severe increase in CD 11b were
found after 8 days repeated IL-1 administrations, which
was associated with decreased IL-10. This result may indi-
cate that astrocyte activation involves an anti-inflammatory
response in acute neuroinflammation. Thus, the findings
demonstrated the first part of our hypothesis that acute
and subacute IL-1 administrations differentially modulate
microglial and astrocyte activities, which may play different
roles in acute and chronic neuroinflammation.
With regards to the role of astrocytes in neurodegeneration,
there are currently two opposite opinions. Heneka and
co-workers found that the reduction in activated micro-
glia and several inflammatory responses in the brain
were parallel with the decrease in Aβ1-42-positive amyl-
oid deposits after treatments with the non-steroid anti-
inflammatory drug ibuprofen [37]. However, ibuprofen
also markedly inhibited reactive astrocytes in this APP
transgenic model. These results support the hypothesis
that astrocyte-induced inflammation contributes to neuro-
degenerative changes. However, it has been also reported
that chronic ibuprofen administration worsens cognitive
functions following traumatic brain injury in rats [38].
On the other hand, some evidence reveals that astrocytes
have neuroprotective functions by inhibiting microglial
activation and neuroinflammation in AD [39,40]. The re-
sults from the present study in glial cell activities and
neurotrophin expression seems to support this later opin-
ion since 8 days repeated IL-1 administration over-
stimulated microglia but suppressed astrocyte functions,
which resulted in the decrease of anti-inflammatory cyto-
kines and BDNF neurotrophin and receptors.
There is a lack of parallel between CD11b mRNA and
protein expressions. Because mRNA expressions are usu-
ally earlier than protein expressions, at a certain time
point, their expression patterns could be at different stages.
Acute and subacute IL-1 treatments induced opposite
changes in the expressions of neurotrophins and their
receptors
For the first time, the present study demonstrated that
acute IL-1 injection markedly up-regulated mRNA and
protein expressions of NGF and BDNF, while 8 days
repeated IL-1 injection down-regulated BDNF mRNA
and protein expression without significantly changing
NGF expression and concentration in the hippocampus.
Many studies have provided solid evidence that neuro-
trophins also act on mature neurons, particularly on in-
jured and degenerated neurons. Studies in animal
models of CNS diseases have shown that neurotrophins
can reduce neuroinflammation and inhibit or delay
neuronal death or degeneration [36,41]. In addition, in-
creased NGF and BDNF expressions may contribute to
the neuroinflammation-induced neuroprotection ob-
served in acute brain injuries and early stages of stroke
[21,42]. Conversely, the deficiency of BDNF or NGF is
believed to be a cause or a trigger of neurodegeneration
Table 2 IL-1β administration-induced changes in concentrations of pro-inflammatory and anti-inflammatory cytokines
in the hippocampus
Acute saline administration Acute IL-1 administration Subacute saline administration Subacute IL-1 administration
IL-1β 1579.3 ± 187.2 2016.3 ± 245.2 1523.53 ± 248.52 4072.07 ± 496.04b
TNF-α 214.63 ± 25.82 1079.74 ± 124.18a 188.03 ± 26.65 1268.01 ± 154.76b
IL-10 91.92 + 9.53 127.72 + 12.64a 98.76 + 6.82 72.35 + 5.47a
Cytokine concentrations were expressed as mean ± SEM in pg/mg protein; aP <0.05 and bP <0.01 versus matched controls (n = 8).
Table 3 A summary of changes in glial cell markers,
neurotrophins and cytokine concentrations in rat
hippocampus after acute and subacute IL-1
administrations
Acute IL-1 Subacute IL-1
qPCR Western or kit qPCR Western or kit
CD11 NS + + ++
GFAP NS + NS _
NGF + + NS NS
BDNF + + _ _
TrK A NS _ NS +
TrK B + NS _ _
p75 _ _ + +




As compared to acute and subacute IL-1 administrations with control groups,
+, significantly up-regulated or increased; -, significantly down-regulated or
decreased and NS, not significantly changed. GFAP, glial fibrillary acidic
protein; NGF, nerve growth factor; BDNF, brain-derived neurotrophic factor;
TrK, tyrosine kinase; APP, amyloid precursor protein.
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[43,44]. Thus, NGF and BDNF, or their receptor agonists,
have been used to treat AD and other neurodegenerative
diseases [12,45,46]. Dr O’Banion’s team has recently dem-
onstrated that chronic over expression of IL-1 impairs
adult hippocampal neurogenesis in the above mentioned
mouse model [47]. Our data suggest that IL-1-induced
dysfunction of neurotrophic system could be a contributor
to the impairment of neurogenesis.
When compared to BDNF, NGF seems less sensitive
to 8 days repeated IL-1 administration in the present
study. A longer term of IL-1 administration may be
needed in the future since we have previously reported
that decreased NGF mRNA expressions were found in
the hippocampus after IL-1 treatment for 8 days [5] or
10 days (unpublished results).
In AD patients and AD models, a decrease in the
BDNF, its receptor, or its precursor form has been
reported [48-50]. An increase in the BDNF concentra-
tion in the dentate gyrus of the hippocampus during ex-
ercise was associated with memory improvement in a
neurodegeneration model of mice [51]. In the present
study, the BDNF mRNA and protein expressions were
up-regulated by acute IL-1 but down-regulated by 8 days
repeated IL-1 administrations. Our results suggest that
in response to acute brain insult or inflammation, both
glial activities and neurotrophic functions are up-regulated
, which may exert protection on the brain, while chronic
inflammation, which increased microglia but suppressed
astrocytes, may damage the neurotrophic system.
The functions of neurotrophin receptors and their re-
lationship with neuroinflammation have also not been
fully studied and understood in neurodegeration. As
mentioned in the introduction, when neurotrophins
combined with TrK receptors, cell survival should be
promoted, while the activation of p75 receptors may
trigger apoptosis. The present study demonstrated for
the first time that acute IL-1 administration increased
TrK B but reduced p75 receptor mRNA and protein ex-
pressions, which further supports the hypothesis that
acute neuroinflammation may provide neuroprotective
effects. Thus, our study demonstrated the second part of
our hypothesis. However, it should be emphasized that
the function of neurotrophin receptors in the brain is
very complicated. For example, pro- and matured
neurotrophins have been found to trigger different types
of receptors [52]. Therefore, p75 receptors not only in-
duce apoptosis but also modulate neurotrophin expres-
sions and functions.
The relationship between neurotrophins and their
receptors and between neurotrophic systems and APP
Decreased TrK A receptors have been previously
reported in the cortex of AD patients [53]. The present
study found up-regulated TrK A protein expressions in
the hippocampus associated with increased APP expres-
sions, but decreased TrK A protein expression in the
cortex (unpublished data) after subacute IL-1 injections,
which may suggest that subacute IL-1 release in the
brain could induce similar AD changes in this receptor.
A publication by D’Onofrio et al. [54] reported that in
AD11 mice, an anti-NGF model (with no significant
change in NGF mRNA expressions), the clusters of
mRNAs that underwent the most changes were in the
inflammatory category. The study also found that on
postnatal day 30, when neurodegeneration and memory
decline were undetectable, the mRNA expressions of
BDNF were up-regulated, while on day 90, when Aβ de-
position and memory decline started, the expressions of
p75 and TrK A receptors were up-regulated but BDNF
was down-regulated in the hippocampus. Another study
has demonstrated that BDNF could inhibit Aβ produc-
tion in primary neurons [55]. The present study demon-
strated that after 8 days repeated IL-1 administration, an
increase in the Aβ precursors APP expressions was asso-
ciated with the decrease in BDNF mRNA and protein
expressions and with the up-regulation of p75 and TrKA
expressions, which provided strong evidence that IL-1β
plays an important role in AD neuropathology.
As p75 receptors are a key ligand for Aβ, dysfunction
of this receptor is linked with the neuropathology of AD;
p75 can directly bind to Aβ1-42, leading to an increase
in the secretion of APP, which produces Aβ and neuro-
toxicity [56], and conversely Aβ accumulation can
stimulate p75 expressions [57]. In AD cortical neurons,
the expression of p75 receptors is higher than in healthy
controls [53]. In the present study, the increases in p75
mRNA and protein expressions were also accompanied by
an increase in APP expressions in the hippocampus, while
IL-1RA reversed the increase in p75 and also reversed
APP expressions. Importantly, this change was only found
after 8 days repeated, but not acute, IL-1 administrations.
Thus, our hypothesis was further demonstrated.
The relevance of IL-1β-induced changes to memory
impairment in the neurotrophic system
Previously, Hein et al. [58] reported that in the mouse
model with sustained hippocampal IL-1 overexpression,
both spatial and contextual memory were impaired,
which could have resulted from microglial activation
and also from other increased inflammatory factors. The
present study further explored microglia activation and
inflammation-induced neurotrophin dysfunction. It is
known that both NGF and BDNF have been found to
enhance acetylcholine release [59,60], while deficiencies
in acetylcholine release and BDNF or NGF expressions
are related to memory impairment in AD patients, as
mentioned in the introduction [5,49-51]. The results
from the present study, in line with neurotrophin
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changes and inflammatory response, showed memory
impairment 4 days after IL-1 administration. The rats
treated with acute IL-1 did not show any memory im-
pairment, as previously acute IL-1 administration has
been found to enhance conditioned fear memory in rats
[61,62]. The memory enhancement associated with acute
IL-1 could be related to the up-regulated NGF, BDNF
and TrK B expressions as observed in the present study.
In this study, memory impairment was associated with
down-regulated BDNF and TrK B and up-regulated TrK
A and p75, and greater expression of p75 receptors in
cholinergic neurons is believed to be responsible for
cholinergic neuronal apoptosis and degeneration [63]. A
previous study also reported that injecting IL-1β into the
hippocampus could block the up-regulation of BDNF
mRNA induced by conditioning memory [64]. The IL-
1RA administration in the current study attenuated sub-
acute IL-1-induced changes in BDNF, p75 and APP with
significant improvement of memory performance in the
radial maze. Therefore, the down-regulation of BDNF
and up-regulation of p 75 may contribute to memory
deficits in the radial maze after 8 days repeated IL-1
administration.
In summary, the present study demonstrated that acute
and subacute IL-1 administration induced different
changes in microglial and astrocyte activities, which cause
opposite responses in neurotrophin expressions. Increased
inflammatory responses, down-regulated BDNF and TrK
B expressions, and up-regulated APP and p75 expressions
may contribute to memory impairment after subacute or
chronic IL-1 administration. However, results obtained
from acute IL-1 administration, such as the up-regulation
of NGF, BDNF and TrK B, increased anti-inflammatory
cytokine IL-10 and down-regulated p75, may explain the
neuroprotective functions of acute microglial and astro-
cyte activation and neuroinflammation in some brain con-
ditions. Future studies should use glial inhibitors and anti-
inflammatory mediators to further demonstrate each step
of the pathway from glial activation to memory impairment.
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